PL2498610T5 - Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej - Google Patents

Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej

Info

Publication number
PL2498610T5
PL2498610T5 PL10830880.0T PL10830880T PL2498610T5 PL 2498610 T5 PL2498610 T5 PL 2498610T5 PL 10830880 T PL10830880 T PL 10830880T PL 2498610 T5 PL2498610 T5 PL 2498610T5
Authority
PL
Poland
Prior art keywords
receptor modulators
synthesis methods
phosphate receptor
chiral synthesis
selective sphingosine
Prior art date
Application number
PL10830880.0T
Other languages
English (en)
Polish (pl)
Other versions
PL2498610T3 (pl
Inventor
Esther Martinborough
Marcus F. Boehm
Adam Richard Yeager
Junko Tamiya
Liming Huang
Enugurthi Brahmachary
Manisha Moorjani
Gregg Alan Timony
Jennifer L. Brooks
Robert Peach
Fiona Lorraine Scott
Michael Allen Hanson
Original Assignee
Receptos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43992106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2498610(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Receptos Llc filed Critical Receptos Llc
Publication of PL2498610T3 publication Critical patent/PL2498610T3/pl
Publication of PL2498610T5 publication Critical patent/PL2498610T5/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
    • A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/12—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
    • C07C245/14—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Agronomy & Crop Science (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10830880.0T 2009-11-13 2010-11-15 Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej PL2498610T5 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26130109P 2009-11-13 2009-11-13
US26247409P 2009-11-18 2009-11-18
EP10830880.0A EP2498610B2 (en) 2009-11-13 2010-11-15 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
PCT/US2010/056760 WO2011060392A1 (en) 2009-11-13 2010-11-15 Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Publications (2)

Publication Number Publication Date
PL2498610T3 PL2498610T3 (pl) 2018-08-31
PL2498610T5 true PL2498610T5 (pl) 2024-11-04

Family

ID=43992106

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10830880.0T PL2498610T5 (pl) 2009-11-13 2010-11-15 Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej
PL18160667T PL3406142T3 (pl) 2009-11-13 2010-11-15 Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18160667T PL3406142T3 (pl) 2009-11-13 2010-11-15 Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej

Country Status (32)

Country Link
US (4) US8362048B2 (enExample)
EP (3) EP2498610B2 (enExample)
JP (3) JP5650233B2 (enExample)
KR (2) KR101752124B1 (enExample)
CN (2) CN102762100B (enExample)
AU (1) AU2010319983B2 (enExample)
BR (2) BR122018077504B8 (enExample)
CA (2) CA2986521C (enExample)
CY (3) CY1120338T1 (enExample)
DK (2) DK3406142T3 (enExample)
EA (2) EA035768B1 (enExample)
ES (2) ES2858337T3 (enExample)
FI (2) FIC20200044I1 (enExample)
FR (1) FR20C1059I2 (enExample)
HR (2) HRP20180874T4 (enExample)
HU (3) HUE054000T2 (enExample)
IL (2) IL219691B (enExample)
LT (3) LT2498610T (enExample)
LU (1) LUC00184I2 (enExample)
MX (1) MX2012005560A (enExample)
MY (2) MY161854A (enExample)
NO (2) NO2498610T3 (enExample)
NZ (1) NZ599915A (enExample)
PH (2) PH12012500939A1 (enExample)
PL (2) PL2498610T5 (enExample)
PT (2) PT3406142T (enExample)
RS (2) RS57253B2 (enExample)
SG (1) SG10201407357PA (enExample)
SI (2) SI3406142T1 (enExample)
SM (2) SMT202100169T1 (enExample)
TR (1) TR201807912T4 (enExample)
WO (1) WO2011060392A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE036391T2 (hu) * 2009-11-13 2018-07-30 Celgene Int Ii Sarl Szfingozin 1 foszfát receptor modulátorok és királis szintézis eljárások
PL2498610T5 (pl) 2009-11-13 2024-11-04 Receptos Llc Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej
US9481659B2 (en) 2011-05-13 2016-11-01 Celgene International Ii Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
MX355261B (es) * 2012-06-21 2018-04-12 Eisai R&D Man Co Ltd Derivado de indanosulfamida novedoso.
WO2014158302A1 (en) * 2013-03-25 2014-10-02 Swenson Rolf Eric Novel sphingosine 1-phosphate receptor antagonists
WO2015066515A1 (en) * 2013-11-01 2015-05-07 Receptos, Inc. Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
US20180016244A1 (en) 2015-04-06 2018-01-18 Auspex Pharmaceuticals, Inc. Deuterium-substituted oxadiazoles
PL3470400T3 (pl) 2016-06-14 2025-08-04 Receptos Llc Krystaliczne postacie ozanimodu i chlorowodorku ozanimodu oraz sposoby ich otrzymywania
RU2754845C2 (ru) * 2016-07-22 2021-09-08 Медшайн Дискавери Инк. Агонист s1p1 и его применение
CN109563059A (zh) * 2016-08-19 2019-04-02 苏州科睿思制药有限公司 奥扎莫德的晶型及其制备方法
WO2018049632A1 (zh) * 2016-09-14 2018-03-22 杭州领业医药科技有限公司 奥扎莫德的晶型、其制备方法及药物组合物
EP3508481A1 (en) * 2016-09-14 2019-07-10 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of ozanimod hydrochloride, and preparation method therefor
CA3038106A1 (en) * 2016-09-29 2018-04-05 Celgene International Ii Sarl Compounds and methods for treating lupus
CN110325517B (zh) * 2017-02-28 2021-03-02 南京明德新药研发有限公司 螺环类化合物及其应用
CN110612292A (zh) * 2017-04-07 2019-12-24 杭州领业医药科技有限公司 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
CN108727292A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 一种奥扎莫德及其中间体的制备方法
CN108727291A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 奥扎莫德及其中间体的制备方法
WO2018208855A1 (en) 2017-05-08 2018-11-15 Celgene International Ii Sarl Sphingosine 1 phosphate receptor agonists for neuroprotection
PT3630738T (pt) * 2017-05-22 2023-10-24 Egyt Gyogyszervegyeszeti Gyar Processo para a produção de ozanimod
WO2018237379A2 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
CN109280035B (zh) * 2017-07-19 2023-06-09 广东东阳光药业有限公司 奥扎莫德的多晶型及其制备方法
WO2019042219A1 (zh) 2017-08-31 2019-03-07 苏州科睿思制药有限公司 奥扎莫德盐酸盐的晶型及其制备方法
WO2019058290A1 (en) * 2017-09-20 2019-03-28 Suven Life Sciences Limited IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND
WO2019094409A1 (en) 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Salts and solid state forms of ozanimod
CN107857760A (zh) * 2017-11-21 2018-03-30 南京天翔医药科技有限公司 鞘氨醇‑1‑磷酸受体调节剂及其应用
JP2021511375A (ja) 2018-01-18 2021-05-06 シージャーヂュアン・サガシティー・ニュー・ドラッグ・デヴェロップメント・カンパニー・リミテッド 三環式化合物の結晶形、塩形及びその製造方法
CN111801096B (zh) 2018-03-20 2024-03-05 卫材R&D管理有限公司 癫痫治疗剂
CN110615747A (zh) * 2018-06-20 2019-12-27 广东东阳光药业有限公司 一种二氢茚中间体的制备方法
EP3810285B1 (en) 2018-06-25 2025-02-12 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
EP3849965A1 (en) 2018-09-12 2021-07-21 Pharmazell GmbH A process for the preparation of ozanimod and its intermediate (s)-1-amino-2,3-dihydro-1h-indene-4-carbonitrile
AR116479A1 (es) * 2018-09-25 2021-05-12 Quim Sintetica S A Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
WO2020115200A1 (en) * 2018-12-07 2020-06-11 Synthon B.V. Improved process for preparing ozanimod
EP3947362A4 (en) * 2019-03-29 2023-01-04 Receptos Llc SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS
CN113891883A (zh) * 2019-03-29 2022-01-04 瑞塞普托斯公司 1-磷酸鞘氨醇受体调节剂
CN113939507A (zh) * 2019-03-29 2022-01-14 瑞塞普托斯公司 1-磷酸鞘氨醇受体调节剂
US20220227722A1 (en) * 2019-04-26 2022-07-21 Receptos Llc Sphingosine 1 phosphate receptor modulator
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
US12404256B2 (en) 2019-07-16 2025-09-02 Synthon B.V. Process for preparing ozanimod
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2021142030A1 (en) * 2020-01-06 2021-07-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
US11760751B2 (en) 2020-03-04 2023-09-19 Helioeast Science & Technology Co., Ltd. Benzo 2-azaspiro[4.4]nonane compound and use thereof
EP4116295B1 (en) * 2020-03-04 2026-06-24 Helioeast Pharmaceutical Co., Ltd. Tricyclic compounds and use thereof
CA3172272A1 (en) 2020-03-17 2021-09-23 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of coronavirus infection
ES3068582T3 (en) * 2020-03-27 2026-06-01 Receptos Llc Sphingosine 1 phosphate receptor modulators
KR20220158745A (ko) * 2020-03-27 2022-12-01 리셉토스 엘엘씨 스핑고신 1 포스페이트 수용체 조절제
US12398112B2 (en) 2020-04-02 2025-08-26 Synthon B.V. Crystalline form of ozanimod hydrochloride
CN111620788B (zh) * 2020-04-20 2022-09-30 广东莱佛士制药技术有限公司 一种制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法
US20240182457A1 (en) * 2021-04-09 2024-06-06 Helioeast Pharmaceutical Co., Ltd. Oxadiazole-substituted spirocyclic compound and application thereof
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2023152767A1 (en) 2022-02-11 2023-08-17 Mylan Laboratories Limited Polymorphic forms of ozanimod hydrochloride
CN121194965A (zh) 2023-05-31 2025-12-23 奎米卡新特缇卡股份有限公司 盐酸奥扎莫德的无定形形式和晶型
AU2024406222A1 (en) 2023-12-20 2026-06-04 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
WO2026035999A1 (en) 2024-08-09 2026-02-12 Triana Biomedicines, Inc. Anaplastic lymphoma kinase (alk) degraders and uses thereof
CN122301787A (zh) * 2024-12-31 2026-06-30 南京易腾药物研究院有限公司 一种季铵盐类局部作用的1-磷酸鞘氨醇受体亚型1激动剂
CN119462405B (zh) * 2025-01-10 2025-05-27 天津阿尔塔科技有限公司 一种氘标记鞘氨醇类化合物和氘标记神经酰胺类化合物的制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479544A (en) 1974-02-07 1977-07-13 American Cyanamid Co 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
FR2628103B1 (fr) * 1988-03-03 1991-06-14 Roussel Uclaf Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides
US5039802A (en) 1990-04-18 1991-08-13 Merck & Co., Inc. Arylation process for preparation of chiral catalysts for ketone reduction
JPH0825973B2 (ja) 1991-04-12 1996-03-13 シェリング・コーポレーション アシル補酵素ａ：コレステロールアシルトランスフェラーゼの阻害剤としての二環式アミド
GB2290790A (en) 1994-06-30 1996-01-10 Merck & Co Inc Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
EP1057827B1 (en) * 1998-01-23 2003-09-10 Sankyo Company Limited Spiropiperidine derivatives
AR035585A1 (es) † 2000-09-15 2004-06-16 Pharmacia Corp Derivados del acido 2-amino-2-alquil-4-heptenoico, composicion farmaceutica y su uso en la fabricacion de medicamentos
US20040058894A1 (en) 2002-01-18 2004-03-25 Doherty George A. Selective S1P1/Edg1 receptor agonists
ATE496024T1 (de) * 2002-12-20 2011-02-15 Merck Sharp & Dohme 1-(amino)indane als edg-rezeptoragonisten
EP4101846B1 (en) 2003-04-11 2023-08-02 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
WO2005032465A2 (en) * 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
US7605171B2 (en) 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
EP1851188A1 (en) 2005-02-22 2007-11-07 Teva Pharmaceutical Industries Limited Improved process for the synthesis of enantiomeric indanylamine derivatives
KR100667075B1 (ko) 2005-07-22 2007-01-10 삼성에스디아이 주식회사 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치
US20080221126A1 (en) † 2005-08-03 2008-09-11 Atadja Peter W Use of Hdac Inhibitors for the Treatment of Myeloma
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
PE20070705A1 (es) * 2005-11-25 2007-08-23 Basf Ag Compuestos de indanil - y tetrahidronaftil-amino-azolina para combatir pestes animales
EP1963509A4 (en) 2005-12-21 2009-07-29 Joseph Gabriele CATECHOLAMINE-REGULATED PROTEIN
WO2007105053A2 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
US20080009534A1 (en) * 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CA2662673A1 (en) * 2006-09-21 2008-03-27 Martin Bolli Phenyl derivatives and their use as immunomodulators
JP2010510250A (ja) 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−燐酸受容体アゴニスト活性を有するヒドリンダンアナログ
RU2009127095A (ru) * 2006-12-15 2011-01-20 Эбботт Лэборетриз (Us) Новые оксадиазольные соединения
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
WO2008106224A1 (en) 2007-02-28 2008-09-04 Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same
GB0725104D0 (en) † 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
US20090298894A1 (en) 2008-04-21 2009-12-03 Asahi Kasei Pharma Corporation Amino acid compounds
PT2291080E (pt) 2008-05-14 2015-10-30 Scripps Research Inst Novos modelamodeladores dos recetores da esfingosina fosfato
US8485794B2 (en) * 2008-06-13 2013-07-16 Doowon Technical College Reciprocating compressor with rotary valve
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
WO2011005290A1 (en) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
GB0911130D0 (en) 2009-06-26 2009-08-12 Glaxo Group Ltd Novel compounds
PL2498610T5 (pl) 2009-11-13 2024-11-04 Receptos Llc Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej
HUE036391T2 (hu) 2009-11-13 2018-07-30 Celgene Int Ii Sarl Szfingozin 1 foszfát receptor modulátorok és királis szintézis eljárások
CN105130922A (zh) 2009-11-13 2015-12-09 瑞塞普托斯公司 选择性的杂环1-磷酸鞘氨醇受体调节剂
US9481659B2 (en) 2011-05-13 2016-11-01 Celgene International Ii Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod

Also Published As

Publication number Publication date
HUE037535T2 (hu) 2018-09-28
SMT201800288T1 (it) 2018-07-17
PL3406142T3 (pl) 2021-08-30
AU2010319983A1 (en) 2012-05-31
SG10201407357PA (en) 2014-12-30
BR112012011427A2 (pt) 2015-10-06
BR112012011427B8 (pt) 2021-05-25
EP2498610B1 (en) 2018-03-14
PT2498610T (pt) 2018-06-19
US10239846B2 (en) 2019-03-26
ES2858337T3 (es) 2021-09-30
CY1124121T1 (el) 2022-05-27
IL219691A0 (en) 2012-07-31
MX2012005560A (es) 2012-10-05
IL267956B (en) 2021-01-31
PH12012500939A1 (en) 2016-06-15
ES2673160T3 (es) 2018-06-20
EP3406142B8 (en) 2021-03-03
WO2011060392A1 (en) 2011-05-19
PH12015502708A1 (en) 2016-10-17
MY161854A (en) 2017-05-15
SI3406142T1 (sl) 2021-08-31
KR20120102704A (ko) 2012-09-18
EP2498610A1 (en) 2012-09-19
IL267956A (en) 2019-09-26
HRP20180874T4 (hr) 2024-09-27
CN105061350B (zh) 2018-05-29
FR20C1059I2 (fr) 2021-12-10
JP2013510885A (ja) 2013-03-28
AU2010319983A2 (en) 2013-09-12
EP2498610A4 (en) 2013-05-22
PL2498610T3 (pl) 2018-08-31
EP3868377A1 (en) 2021-08-25
EP3406142B1 (en) 2020-12-23
US20170320839A1 (en) 2017-11-09
HUS2000045I1 (hu) 2020-12-28
CA2780772A1 (en) 2011-05-19
MY189750A (en) 2022-03-02
EA201690391A1 (ru) 2016-08-31
NZ599915A (en) 2014-07-25
JP2014122208A (ja) 2014-07-03
JP5650233B2 (ja) 2015-01-07
HRP20210446T1 (hr) 2021-05-14
US20110172202A1 (en) 2011-07-14
LTC2498610I2 (lt) 2022-06-10
CY1120338T1 (el) 2019-07-10
LTPA2020533I1 (lt) 2020-12-10
JP2015038145A (ja) 2015-02-26
US20150299149A1 (en) 2015-10-22
US9388147B2 (en) 2016-07-12
LT3406142T (lt) 2021-06-10
CA2986521A1 (en) 2011-05-19
DK2498610T4 (da) 2024-09-09
EP2498610B2 (en) 2024-06-19
JP5982705B2 (ja) 2016-08-31
NO2020039I1 (no) 2020-11-18
CN102762100A (zh) 2012-10-31
HK1213874A1 (zh) 2016-07-15
KR101721716B1 (ko) 2017-04-10
CA2780772C (en) 2018-01-16
SI2498610T1 (en) 2018-07-31
LT2498610T (lt) 2018-06-11
HRP20180874T1 (hr) 2018-07-13
NO2498610T3 (enExample) 2018-08-11
EA201290323A1 (ru) 2013-05-30
ES2673160T5 (es) 2024-11-19
US8362048B2 (en) 2013-01-29
CY2020035I1 (el) 2021-03-12
HUE054000T2 (hu) 2021-08-30
EP3406142A1 (en) 2018-11-28
LUC00184I2 (enExample) 2024-07-01
PT3406142T (pt) 2021-03-26
TR201807912T4 (tr) 2018-06-21
KR101752124B1 (ko) 2017-06-28
KR20160149317A (ko) 2016-12-27
RS61829B1 (sr) 2021-06-30
EA024801B1 (ru) 2016-10-31
AU2010319983B2 (en) 2015-03-12
EA035768B1 (ru) 2020-08-07
FIC20200044I1 (fi) 2020-11-18
CA2986521C (en) 2020-06-30
SMT202100169T1 (it) 2021-07-12
CN102762100B (zh) 2015-07-01
BR122018077504B8 (pt) 2021-05-25
RS57253B2 (sr) 2024-10-31
DK3406142T3 (da) 2021-03-22
FR20C1059I1 (enExample) 2020-12-25
HK1175948A1 (en) 2013-07-19
BR112012011427B1 (pt) 2021-04-20
PH12015502708B1 (en) 2018-06-06
BR122018077504B1 (pt) 2021-05-11
CN105061350A (zh) 2015-11-18
IL219691B (en) 2019-07-31
SI2498610T2 (sl) 2024-10-30
RS57253B1 (sr) 2018-08-31
US20130231326A1 (en) 2013-09-05
DK2498610T3 (en) 2018-06-14
CY2020035I2 (el) 2021-03-12
FI2498610T4 (fi) 2024-08-29

Similar Documents

Publication Publication Date Title
PL3406142T3 (pl) Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej
EP2498611A4 (en) SPHINGOSINE-1 PHOSPHATE RECEPTOR MODULATORS AND METHOD FOR CHIRAL SYNTHESIS
BRPI0907844A2 (pt) moduladores seletivos do receptor de andrógeno
EP2303378A4 (en) INTERFACE
BRPI0909656A2 (pt) Microencapsulamento
DK2235384T3 (da) Forbindelsesindretning
IL223044B (en) Estrogen receptor modulators and uses thereof
DK2262808T3 (da) Chemokinreceptormodulatorer
BRPI0914743A2 (pt) estrutura
DK2297100T3 (da) Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer
DK2837348T3 (da) Kryokirurgiske fremgangsmåder
BRPI0918064A2 (pt) distribuidor de substância
DK2512451T3 (da) Modulator
BRPI0911625A2 (pt) Métodos
PL2414983T3 (pl) Bezpieczny system danych
BRPI0909287A2 (pt) Retenção
FI20085899A0 (fi) Puu-Metalli-komposiittirakenne
EP2441772A4 (en) FROST PROTECTION SUBSTANCE
BRPI0916695A2 (pt) tampão
DK2265778T3 (da) Muranker
ES1071297Y (es) Tapon mejorado
ES1075833Y (es) Tapon
FI20080591A0 (fi) Eleillä ohjattava käyttöliittymä
NO20081851L (no) Anordning til PC
SE0800697L (sv) Förankringsanordning